Aviceda Announces Dosing of First Patient With AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration, in the Phase 2 SIGLEC Trial

By / 01/06/2023

Aviceda Therapeutics announced the dosing of its first patient with AVD-104 in its Phase 2 SIGLEC Trial today by Ashkan Abbey, MD of Texas Retina Associates in Dallas.